Spiral Therapeutics Secures $27 Million in Series B Funding and Collaborates with Advanced Bionics

Spiral Therapeutics Secures $27 Million Series B Financing

On April 14, 2026, Spiral Therapeutics, a pioneering biotechnology firm focused on developing innovative therapies for inner ear disorders, announced the successful close of its $27 million Series B financing. This funding round, which is led by Gund Investment, sees new strategic support from industry giants such as Advanced Bionics and a notable global pharmaceutical company. The round also enjoyed continued contributions from existing backers, including Ferring Ventures and the Uni-Bio Science Group.

The newly raised capital will enable Spiral to advance its development pipeline while fostering a strategic collaboration with Advanced Bionics aimed at enhancing treatment outcomes through sustained local drug delivery during cochlear implantation. Hugo Peris, the Founder and CEO of Spiral, expressed optimism about the funding, highlighting its significance as a key milestone for the company. He noted that the partnership will facilitate substantial advancements in the treatment of inner ear disorders, an area that has historically lacked innovative solutions despite its prevalence.

Spiral's lead therapeutic program, SPT-2101, has shown promising results in clinical trials, significantly reducing overall vertigo symptoms in patients suffering from Ménière's disease. With preparations underway for a registrational clinical trial, the company is keen to establish itself as a leader in addressing unmet medical needs related to inner ear conditions. Furthermore, Spiral's proprietary MICS™ (Minimally-Invasive Cochlear System) drug delivery platform is at the heart of its broader portfolio of initiatives aimed at mitigating hearing loss and other related inner ear diseases.

Despite the substantial impact of inner ear disorders on patients' quality of life, the therapeutic space surrounding these conditions has seen limited innovation. Spiral Therapeutics aims to rectify this disparity by leveraging precision delivery technologies, which promise to unlock new treatment paradigms across multiple otologic indications. The collaboration with Advanced Bionics is anticipated to enhance the efficacy of cochlear implants through innovative drug delivery methods.

As the company continues to expand its footprint in the biotechnology arena, it remains committed to developing effective therapies that cater to the unique needs of individuals with inner ear disorders.

In summary, the completion of this $27 million Series B financing marks a turning point for Spiral Therapeutics, setting the stage for innovative advancements in the treatment of inner ear disorders through collaborative efforts with key industry players. With a strong pipeline and a dedicated focus on addressing significant unmet needs, Spiral is poised to make meaningful changes in the landscape of otologic medicine.